E2F6P4: A Potential Drug Target and Biomarker (G139542)

Target Name: E2F6P4

NCBI ID: G139542

E2F6P4

Other Name(s): E2F transcription factor 6 pseudogene 4

E2F6P4: A Potential Drug Target and Biomarker

E2F6P4, also known as E2F-6p4, is a protein that plays a critical role in the regulation of gene expression and cell proliferation. It is a key transcription factor that is involved in the transcription of many genes, including some that are associated with cancer .Recent studies have identified E2F6P4 as a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

The E2F gene family is a family of transcription factors that are involved in the regulation of gene expression. The E2F6P4 gene is a member of this family and is expressed in many different tissues and cells. It is well-known for its role in the regulation of cell proliferation and has been implicated in the development and progression of many diseases.

One of the key functions of E2F6P4 is its ability to induce the expression of many different genes. This is accomplished through the formation of a complex with the transcription factor SAF-3, which allows E2F6P4 to physically interact with the protein and cause it to activate the genes it is responsible for regulating.

E2F6P4 has been shown to play a role in the regulation of many different genes that are involved in various cellular processes, including cell growth, differentiation, and apoptosis (programmed cell death). It has been shown to be involved in the development and progression of many diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

One of the ways that E2F6P4 is involved in the development of cancer is through its role in the regulation of the angiogenic gene network. The angiogenic gene network is a group of genes that are involved in the development and maintenance of blood vessels, and it is thought to play a key role in the development of cancer.

E2F6P4 has been shown to be involved in the regulation of genes that are involved in the angiogenic network, including the vascular endothelial growth factor (VEGF) gene. VEGF is a potent angiogenic factor that is involved in the development and maintenance of blood vessels, and it has been implicated in the development of many different types of cancer.

E2F6P4 has also been shown to be involved in the regulation of the Notch signaling pathway, which is a critical pathway involved in the development and maintenance of tissues and organs. Notch signaling is thought to play a key role in the development of many different types of cancer, including neurodegenerative diseases and psychiatric disorders.

In addition to its role in the development and progression of cancer, E2F6P4 is also involved in the regulation of many other genes that are involved in various cellular processes. It is a known regulator of the T-cell receptor (TCR), which is involved in the development and activation of T cells, and it has been shown to play a key role in the regulation of immune responses.

E2F6P4 is also involved in the regulation of cell signaling pathways that are involved in cell adhesion, migration, and invasion. It is a known regulator of the PDGF signaling pathway, which is involved in the development and maintenance of tissues and organs, and it has has been shown to play a key role in the regulation of cell signaling pathways that are involved in cell adhesion and migration.

In addition to its role in the regulation of many different genes, E2F6P4 is also involved in the regulation of cellular processes that are important for the survival and survival of cells. It is a known regulator of the DNA damage repair pathway, which is involved in the regulation of DNA repair and is thought to play

Protein Name: E2F Transcription Factor 6 Pseudogene 4

The "E2F6P4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about E2F6P4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets